PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-97.35%
Negative net income growth while CRWV stands at 7.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
16.77%
D&A growth well above CRWV's 26.15%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-592.24%
Negative yoy deferred tax while CRWV stands at 3.70%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
1.99%
Slight usage while CRWV is negative at -110.52%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.99%
Lower 'other working capital' growth vs. CRWV's 112.72%. David Dodd would see fewer unexpected short-term demands on cash.
11744.12%
Well above CRWV's 23.14%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-10.84%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-21.97%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
30.27%
Purchases growth of 30.27% while CRWV is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-31.91%
Both yoy lines are negative, with CRWV at -100.00%. Martin Whitman suspects an environment prompting fewer sales or fewer maturities within the niche.
No Data
No Data available this quarter, please select a different quarter.
9.74%
We have mild expansions while CRWV is negative at -70.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
32.24%
Stock issuance far above CRWV's 4.88%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
-106.83%
We cut yoy buybacks while CRWV is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.